FDC Ltd

FDC Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

FDC Ltd

₹ 444 1.21%
10 Jun - close price
fdcindia.com BSE: 531599 NSE: FDC
About

FDC (Fairdeal Corporation) Ltd Limited (found in 1936) is among India’s leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialized formulations, and among the world’s foremost manufacturers and marketers of Oral Rehydration Salts (ORS). Some of FDC’s leading brands in India include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zathrin, Zipod, Cotaryl and Mycoderm in the domestic and international markets.[1]

Key Points

Revenue Breakup
Anti-infective medicines contribute 42% of revenues, followed by gastro intestinal 24%, vitamins/ minerals 7%, ophthalmology 6%, cardiac 7%, dermatology 4% and others 11%.[1]

Website BSE NSE
  • Market Cap ₹ 7,221 Cr.
  • Current Price ₹ 444
  • High / Low ₹ 659 / 359
  • Stock P/E 27.1
  • Book Value ₹ 140
  • Dividend Yield 1.13 %
  • ROCE 16.4 %
  • ROE 12.2 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • The company has delivered a poor sales growth of 9.46% over past five years.
  • Company has a low return on equity of 12.0% over last 3 years.
  • Working capital days have increased from 73.9 days to 118 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE SmallCap BSE Allcap BSE 250 SmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
341 495 445 409 435 536 486 458 462 638 514 464 492
322 417 378 360 386 414 410 374 406 492 444 417 438
Operating Profit 19 78 67 49 49 122 76 84 56 147 70 47 54
OPM % 6% 16% 15% 12% 11% 23% 16% 18% 12% 23% 14% 10% 11%
10 19 13 18 7 29 27 25 20 28 35 19 16
Interest 1 1 1 1 1 1 1 1 1 1 1 1 1
Depreciation 9 9 10 10 10 10 10 10 10 11 14 13 16
Profit before tax 19 87 69 57 45 141 93 98 65 163 90 51 53
Tax % 45% 19% 25% 28% 32% 22% 25% 19% 29% 27% 20% 28% 27%
10 71 52 41 31 110 70 79 46 119 72 37 39
EPS in Rs 0.62 4.26 3.12 2.46 1.85 6.62 4.29 4.87 2.84 7.31 4.42 2.28 2.38
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
845 888 994 1,013 1,074 1,089 1,341 1,331 1,525 1,784 1,943 2,108
638 690 765 769 841 860 1,038 997 1,271 1,533 1,604 1,783
Operating Profit 207 199 229 243 233 229 304 334 254 251 339 325
OPM % 24% 22% 23% 24% 22% 21% 23% 25% 17% 14% 17% 15%
39 46 39 44 45 42 57 95 76 50 102 91
Interest 3 2 1 1 1 1 3 3 3 4 4 5
Depreciation 25 39 34 35 35 33 37 38 37 39 40 54
Profit before tax 218 204 232 252 241 237 320 388 289 258 396 357
Tax % 38% 27% 27% 25% 28% 28% 25% 22% 25% 25% 23% 25%
135 148 169 189 174 170 240 301 216 194 305 267
EPS in Rs 7.61 8.33 9.48 10.60 9.95 9.74 14.03 17.85 12.82 11.70 18.75 16.39
Dividend Payout % 30% 27% 24% 21% -0% -0% 6% -0% -0% -0% -0% 61%
Compounded Sales Growth
10 Years: 9%
5 Years: 9%
3 Years: 11%
TTM: 9%
Compounded Profit Growth
10 Years: 7%
5 Years: 3%
3 Years: 8%
TTM: -8%
Stock Price CAGR
10 Years: 12%
5 Years: 12%
3 Years: 23%
1 Year: -1%
Return on Equity
10 Years: 14%
5 Years: 13%
3 Years: 12%
Last Year: 12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 18 18 18 18 18 18 17 17 17 17 16 16
Reserves 827 919 1,065 1,252 1,259 1,428 1,530 1,717 1,940 1,965 2,081 2,265
3 2 1 1 1 1 15 15 32 28 21 21
211 210 182 197 228 194 250 207 281 333 350 412
Total Liabilities 1,059 1,148 1,266 1,468 1,505 1,640 1,813 1,956 2,270 2,343 2,468 2,714
284 393 675 678 674 682 674 689 705 699 680 852
CWIP 18 29 20 6 13 12 24 19 105 198 261 136
Investments 417 489 325 491 471 585 665 790 886 806 843 1,028
340 237 246 293 348 360 451 458 575 640 684 698
Total Assets 1,059 1,148 1,266 1,468 1,505 1,640 1,813 1,956 2,270 2,343 2,468 2,714

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
150 128 174 154 150 112 250 207 162 155 221 318
-55 -89 -73 -144 21 -121 -98 -77 -145 11 -17 -200
-75 -48 -97 0 -169 -0 -142 -129 -10 -180 -202 -92
Net Cash Flow 19 -9 4 11 1 -8 10 1 7 -14 2 26

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 26 25 23 27 28 29 34 30 20 25 22 19
Inventory Days 116 132 134 148 166 184 180 189 210 183 216 186
Days Payable 90 94 84 81 101 82 101 68 94 99 103 102
Cash Conversion Cycle 51 64 72 94 93 131 113 152 135 109 135 103
Working Capital Days 2 11 21 23 29 45 41 50 47 49 54 118
ROCE % 25% 21% 22% 21% 19% 17% 21% 22% 15% 13% 18% 16%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
69.50% 69.49% 69.49% 69.49% 69.49% 69.66% 69.66% 69.66% 69.66% 69.66% 69.66% 69.66%
4.34% 3.99% 3.77% 3.80% 2.06% 2.42% 2.43% 2.65% 2.51% 2.62% 2.67% 2.56%
6.07% 6.77% 7.76% 8.27% 9.13% 8.12% 7.76% 6.94% 6.72% 6.02% 6.08% 6.37%
20.09% 19.75% 18.98% 18.44% 19.32% 19.80% 20.15% 20.76% 21.11% 21.71% 21.60% 21.42%
No. of Shareholders 65,31863,17259,87157,01256,71756,92855,34152,37750,63455,40055,22853,880

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls